Loading…
Employees: 33,858
Size GMR Solutions (GMRS) is a United States Health Care company (Medical/Nursing Services) with a market value of $672M, the 2516th largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.44 on 6 Nov 2026.
Growth Revenue fell 4.0% over the last twelve months (peer median +6.7%); the operating margin is 14.4% (peer median 7.2%).
Valuation It trades at 8.0× forward earnings against a peer median of 21.5× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -20% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.4 points above its cost of capital (5.5% WACC).
Short interest Short interest is 8.3% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | $5.74B | $5.98B | $5.39B |
| Revenue growth | — | -4% | +11% | — |
| Gross profit | n/a | $1.90B | $2.14B | $1.76B |
| EBITDA | n/a | $1.15B | $1.02B | $736M |
| Net income | n/a | $206M | $20.4M | -$203M |
| Free cash flow | n/a | $383M | -$22.4M | $86.7M |
| Capital expenditure | n/a | $259M | $269M | $171M |
| Total debt | $4.75B | $5.37B | $4.86B | n/a |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GMRS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.0% | -3.2% | 2nd highest of 21 |
| Distance from 52-week high | -22.1% | -28.8% | 8th highest of 21 |
| Revenue growth (TTM) | -4.0% | +6.7% | 4th lowest of 21 |
| Operating margin | 14.4% | 7.2% | 3rd highest of 21 |
| Forward P/E | 8.0× | 21.5× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -20.0% | 10.6% | least demanding of 17 |
| Growth delivered (Del g) | -4.0% | +11.5% | 2nd lowest of 17 |
| Hurdle (Req g minus delivered) | -16.0 pp | +0.7 pp | 4th least demanding of 17 |
| ROIC minus cost of capital | +7.4 pp | -2.2 pp | 4th highest of 20 |
| EV / EBITDA | 4.3× | 10.3× | cheapest of 13 |
| Net debt / EBITDA | 3.7× | 1.6× | 3rd most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 8.0× | -20.0% | -4.0% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 41.9× | 35.7% | +31.6% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | n/a | 8.8% | +3.2% |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 35.2× | 27.9% | +10.9% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 11.1× | -4.6% | +5.3% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 67.4× | n/a | n/a |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | n/a | n/a | n/a |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 15.5× | 8.3% | +17.7% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 13.9× | 8.1% | +42.6% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 17.3× | 3.9% | +2.6% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 25.5× | 12.0% | -1.5% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | n/a | 22.4% | -5.8% |